Mehrnaz Nazari Rad - Department of Pediatrics, School of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Javad Akhondian - Pediatric Neurology Ward, Mashhad University of Medical Sciences
Seyed Ali Alamdaran - Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Aramesh Rezaeian - Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Ali khakshour - Assistant Professor of Pediatric. Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra Abbasi Shaye - Clinical Research Development Center, Akbar Hospital, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran
Seyed Javad Sayedi - Assistant Prof of Pediatric Pulmonology, Mashhad University of Medical Sciences

Background: Cerebral palsy stands as the main cause of mobility disability in childhood, and the accompanying sialorrhea exacerbates health and psychological issues for both the child and the family. We aimed to assess the effect of botulinum toxin type A on reducing sialorrhea in children with cerebral palsy.Methods: This self-controlled clinical trial was executed among children afflicted with cerebral palsy. The Teacher Drooling Scale was used as the data collection tool. The intervention involved the administration of botulinum toxin A, with a dosage ranging from ۳۰ to ۵۰ units in each parotid gland, skillfully guided by a radiologist using ultrasound. Sialorrhea scores were compared before and after the injection.Results: Our study included ۲۱ children with cerebral palsy and sialorrhea. After the two post-injection weeks, a noteworthy drop was observed in the sialorrhea score (۴.۱۰±۰.۸۳۱) compared to the pre-injection score (۴.۷۱±۰.۴۶۳). The sialorrhea score until the ninth month after injection (۱.۱۲۱±۳.۴۳) was still significantly lower than the score before injection.Conclusion: The injection of botulinum toxin A emerges as a potent medication, significantly curtailing the drooling among patients with cerebral palsy. This finding can be used to prevent aspiration pneumonia and reduce social and psychological complications in this population.

Botulinum Toxins Type A,,, ,،Cerebral palsy,,, ,،Sialorrhea